Litton Mark James 4
4 · Athira Pharma, Inc. · Filed Feb 16, 2024
Insider Transaction Report
Form 4
Litton Mark James
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-02-15+650,000→ 650,000 totalExercise: $3.66Exp: 2034-02-14→ Common Stock (650,000 underlying)
Footnotes (1)
- [F1]Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.